Research interests include targeted therapy of urologic malignancies with special emphasis on monoclonal antibodies and antibody fusion molecules as new therapeutic reagents. Major current projects include detection of differentially expressed molecules in different responder populations and in prostate cancer (versus normal prostate and other normal tissues) through array analyses and proteome analyses, and the development of (redirected) tumour-specific adenoviral vectors.
Egbert Oosterwijk heads the immuno- and gene therapy programme of the section Experimental Urology. He is associated professor in the Urology department. He is also an affiliated member of the Ludwig Institute for Cancer Research, New York, USA.
<< go back